Preoperative Prediction of a Rare and Highly Aggressive Subtype of Hepatocellular Carcinoma Based on Multimodal Imaging and Clinical Indicators.

Abstract

Purpose: To develop and validate a reliable preoperative non-invasive diagnostic model for dual-phenotype hepatocellular carcinoma (DPHCC) by integrating multimodal imaging and clinical indicators, thereby facilitating clinical decision-making.

Patients and methods: 222 pathologically confirmed patients (61 with DPHCC, 161 with non-DPHCC) were retrospectively enrolled in this study and randomly assigned to training and validation cohorts in an 8:2 ratio. Serological and multimodal imaging characteristics were analyzed. Univariate and multivariate logistic regression analyses identified independent DPHCC predictors and built a nomogram. Model performance and clinical utility were assessed by receiver operating characteristic (ROC) and decision curve analysis (DCA) curve respectively. The calibration curve was used to verify the model. Recurrence-free survival (RFS) was assessed using Kaplan-Meier and Log rank tests.

Results: In multivariate analysis, age (OR=0.91; P < 0.001), LDH (OR=1.03; P=0.002), PT (OR=0.14; P < 0.001), AFP (OR=4.04; P=0.019), Adler grade (OR=0.17; P=0.037), non-enhancing area (OR=8.30; P=0.004), arterial phase hyperenhancement (OR=0.12; P=0.015) and enhancing capsule (OR=0.32; P=0.04) were independent predictors of DPHCC. The nomogram achieved a robust predictive performance with C-index (0.92 vs 0.87) and accuracy (0.87 vs 0.86) in the training and validation cohorts. In addition, the calibration curve and DCA also showed good model performance. DPHCC patients had significantly lower RFS than non-DPHCC patients (P = 0.037).

Conclusion: A nomogram was established for non-invasive prediction of DPHCC risk utilizing multimodal imaging combined with clinical indicators to help achieve personalized treatment.